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Abstract   
 
Abnormalities in hippocampal morphology are characteristic of schizophrenia and 
have also been reported in chronic cannabis users. There is a paucity of research 
investigating potential additive effects of cannabis use on brain pathology associated 
with schizophrenia. In this study we performed hippocampal shape analysis in 
cannabis-using and non-using patients with schizophrenia, healthy cannabis users and 
healthy non-using controls. Hippocampal shape changes were observed in each group 
relative to controls, with the greatest degree of alterations (i.e., deflations across the 
hippocampus, and with an anterior predisposition), in cannabis-using schizophrenia 
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1. Introduction 
 
Cannabis use is highly comorbid with schizophrenia (Koskinen et al., 2010) and 
considered a component cause of the disorder (D’Souza et al., 2009; Murray et al., 
2007). There is growing evidence that long-term or heavy cannabis use impacts upon 
brain structure and function, particularly in regions known to be affected in 
schizophrenia, such as the hippocampus (Ashtari et al., 2011; Lorenzetti et al., 2010; 
Solowij and Michie, 2007; Solowij et al., 2012). We have previously reported dose-
related reductions in hippocampal volume in otherwise healthy chronic cannabis users 
that were associated with subclinical positive psychotic symptoms (Yücel et al., 2008), 
and were of a magnitude similar to that observed in schizophrenia (e.g. Velakoulis et 
al., 1999). A key question is whether effects associated with comorbid chronic 
cannabis use and schizophrenia exceed those associated with either condition 
occurring in isolation. 
 
We sought to address this question by assessing hippocampal volume and performing 
hippocampal shape analysis to inform regional specificity in healthy cannabis users 
and in cannabis using and non-using patients with schizophrenia. In line with a recent 
study that reported greater hippocampal shape alterations in patients with 
schizophrenia and prior comorbid alcohol use disorders (Smith et al., 2011), we 
hypothesised that cannabis use would exert an additional effect on the hippocampal 
pathology typically observed in schizophrenia, particularly in the anterior 
hippocampus (Csernansky et al., 2002; Small et al., 2011; Tamminga et al., 2010).   
 
 
2. Experimental/Materials and Methods 
 
2.1 Participants, substance use and clinical measures 
Seventeen medicated patients with schizophrenia, 15 long-term heavy cannabis users 
(THC) and 16 healthy controls (CON), all right handed males, were recruited from the 
general community, by referral from psychiatrists or through the Australian 
Schizophrenia Research Bank register, and provided written informed consent. Eight 
of the patient group were long-term cannabis users (SZ+THC), with similar extensive 
levels of use as the healthy THC group (near daily for 10–32 years), while nine 
patients had never used cannabis regularly (SZ–THC). No participant had used any 
other illicit substance >10 times and alcohol use was limited to <24 standard drinks 
per week. All groups were matched on age (range 21-60 years), premorbid IQ 
(National Adult Reading Test) and education, but alcohol and tobacco use differed 
between groups. Demographic, clinical and substance use characteristics (elicited by 
structured interview) are provided in Table 1 (see also Solowij et al., 2011).    
 
The Structured Clinical Interview for DSM-IV Axis I Disorders was used to exclude 
psychiatric disorders among healthy participants and to confirm a schizophrenia 
diagnosis in patients. Psychotic symptoms were assessed using the Scales for the 
Assessment of Positive and Negative Symptoms (SAPS and SANS; Andreasen, 1983). 
Healthy cannabis users had significantly higher SAPS (z=3.57, p<.0005) and SANS 
(z=3.66, p<.0005) scores than controls. The two patient groups (SZ+THC and SZ–
THC) did not differ in symptom scores (SAPS: p>.19; SANS: p>.09), which were 
higher than those observed in the healthy cannabis users (THC vs. SZ+THC, SAPS: 
z=3.07, p=.002; SANS: z=3.39, p=.001; THC vs. SZ–THC, SAPS: z=1.88, p=.060, 
SANS: z=2.69, p=.007). All protocols were approved by university and regional 
health ethics committees.  
 
2.2 Neuroimaging procedures, measurements and statistical analyses 
MRI data were acquired from a 3-Tesla scanner using a volumetric SPGR sequence 
with 180 contiguous coronal slices (TE, 2.9ms; TR, 6.4ms; flip-angle, 8o; matrix-size, 
256x256; 1mm3 voxels).  
 
Hippocampal volumes were measured using established protocols (Velakoulis et al., 
1999) and delineated by a trained rater blind to group information (see Yücel et al, 
2008). Left and right hippocampal volumes were compared between groups by 
ANOVA. Shape analysis was undertaken in a semi-automated fashion using the 
University of North Carolina shape analysis toolkit - spherical harmonic shape 
description (SPHARM-PDM; Brechbuhler et al., 1995); a detailed description of the 
methodology is available in Styner et al. (2004; 2006). We utilized MANCOVA 
within SPHARM-PDM to control for alcohol and tobacco use in between-group 
analyses, while controlling for multiple comparisons using the false discovery rate 
(FDR) correction procedure (Paniagua et al., 2009; Pantazis et al., 2004; Styner et al., 
2004), and the toolkit’s correlational analysis to calculate Spearman’s correlations 








3.1 Hippocampal volume 
Neither tobacco nor alcohol use correlated with hippocampal volumes in the entire 
sample (cigarettes/day: left: -.09, p=.66; right: -.13, p=.52; standard drinks/day: left: -
.18, p=.29; right: -.14, p=.42) or in any subgroup, and were therefore not included as 
covariates. The overall difference between the 4 groups was significant for both left 
and right hippocampus (Table 1) with the THC group having smaller hippocampi 
bilaterally than CON (left: F1,29=9.25, p=.005; right: F1,29=11.05, p=.002). The THC 
group did not differ from either of the schizophrenia groups (SZ+THC: left p=.18, 
right p=.15; SZ–THC: left p=.11, right p=.62). The SZ+THC group did not differ 
significantly from controls (left p=.26, right p=.25), whereas SZ–THC had smaller 
right (F1,23=5.33, p=.03) but not left (p=.23) hippocampi than CON. Combining the 
two schizophrenia groups confirmed a significant difference from CON for the right 
(F1,31=4.88, p=.035) but not left (p=.14) hippocampus. SZ+THC and SZ–THC did not 
differ in volume (left p=.96, right p=.39).  
 
3.2 Between-group shape comparisons 
Fig. 1 shows the raw and FDR-corrected p-value and difference maps from between-
group comparisons of hippocampal shape, with each clinical group compared against 
CON. Regional shape alterations were observed in each group, but only the large 
reductions (areas of deflation up to 4mm) in the left hippocampus of the SZ+THC 
group survived the conservative FDR correction. The overall shape change in the left 
hippocampus was significant between SZ+THC and CON (p=.003), falling just short 
of significance on the right (p=.058) (with areas of deflation up to 2mm). SZ–THC 
showed shape alterations in regions of the head and body of the hippocampus, with 
areas of deflation of approximately 2mm in the left and 1.5mm in the right 
hippocampus. The overall shape change across the surface showed trend level 
significance for SZ–THC compared to CON (p=.056) in the left hippocampus, but not 
in the right (p=.24). Similarly, THC showed bilateral differences compared to CON, 
with larger regions of deflation in the right hippocampus, and of a similar magnitude 
to that observed in SZ–THC. There was a significant overall shape change for THC 
compared to CON in the right hippocampus (p=.045), with a trend in the left 
hippocampus (p=.085). The same pattern of results was obtained after covarying for 
alcohol and tobacco use. 
 
3.3 Correlational shape analyses 
The cumulative dose of exposure to cannabis, amount and frequency of use in the past 
month, and duration of use, all showed significant negative correlation with 
hippocampal shape in the cannabis-using group as a whole (THC and SZ+THC) 
(examples shown in Fig. 2), suggesting greater regional deflation with greater 
exposure to cannabis. Duration of illness in the schizophrenia group as a whole 
(SZ+THC and SZ–THC) correlated with the shape of some regions of the 
hippocampal head, being reduced with increasing years of illness. SAPS and SANS 
symptom scores correlated with hippocampal shape in the THC, SZ+THC and SZ–
THC groups, most prominently in SZ+THC, with both positive and negative 
symptom scores showing a strong correlation with widespread hippocampal deflation 
bilaterally (Fig. 3). However, none of these correlations survived FDR correction, 




Hippocampal pathophysiology is evident in a diverse range of disorders that appear to 
differentially target distinct subregions of the hippocampus (Small et al., 2011). 
Despite our limited sample size, shape analysis determined additive effects of 
cannabis to the hippocampal pathology evident in schizophrenia, when significant 
volumetric differences were not observed between patients who used cannabis and 
those that did not. The regional specificity of changes in the shape of the 
hippocampus in SZ+THC, most significant in the tip of the tail, head and midway 
down the body, supports the sensitivity of shape analysis to detecting alterations in 
the absence of a volume difference. The global shape change in the THC group, on 
the other hand, suggests more diffuse alterations that parallel the overall volume 
reduction observed. Cannabis exposure in both groups was associated with deflations 
in anterior and medial areas that may correspond to the dentate gyrus and CA3/4 
regions. We also observed strong associations between hippocampal regional 
deflations and psychotic symptoms in the cannabis-using schizophrenia patients, 
findings that require replication with a larger sample.  
 
While the mechanism underlying hippocampal shape changes is not known, the 
altered regions are dense with cannabinoid receptors (Glass et al., 1997), which may 
be dysfunctional in the pathology of schizophrenia and as a result of long-term 
exposure to cannabis (Villares, 2007). Our findings support an interpretation of dose-
dependent neurotoxic effects, broadly across the hippocampus, as evidenced also by 
animal studies (see Solowij et al., 2012). The combined effects of comorbid chronic 
cannabis use and schizophrenia appear to exceed those of either condition occurring 
in isolation, consistent with other recent studies (Habets et al., 2011; Rais et al., 2008; 
Solowij et al., 2011). Future studies with larger samples could examine further gender 
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Fig. 1. Shape statistical analysis significance maps showing comparisons between 
schizophrenia patients without cannabis use (SZ+THC) versus healthy controls 
(CON) (top), schizophrenia patients with cannabis use (SZ–THC) versus CON 
(middle) and healthy cannabis users (THC) versus CON (bottom). Left hippocampus 
is depicted on the left and right hippocampus on the right, displaying superior and 
inferior views. For each view, raw p-value maps, FDR-corrected p-value maps, and 
mean difference magnitude displacement maps are shown (the latter visualising group 
test local effect size by displaying the magnitude of deflation (in mm) between the 
same point on the mean surface of each group (Styner et al., 2006)). 
 
Fig. 2. Correlations in the entire cannabis-smoking group (THC and SZ+THC) 
between hippocampal shape and cumulative exposure to cannabis over the past 10 
years (top) and frequency of cannabis use in the past month (bottom), with left 
hippocampus on the left and right hippocampus on the right, displaying superior and 
inferior views. Raw p-value maps and Spearman’s rho-value maps are shown. The 
significance of these correlations did not survive FDR correction (FDR-corrected p-
value maps not shown).  
 
Fig. 3. Correlations in the cannabis-using schizophrenia group (SZ+THC) between 
hippocampal shape and positive symptoms (SAPS score; top) and negative symptoms 
(SANS score; bottom), with left hippocampus on the left and right hippocampus on 
the right, displaying superior and inferior views. Raw p-value maps and Spearman’s 
rho-value maps are shown. The significance of these correlations did not survive FDR 
correction (FDR-corrected p-value maps not shown). 
  











Age 39.8 (8.9) 36.4 (9.8) 37.5 (6.6) 44.1 (8.6) 0.21 
IQ 109.2 (6.3) 113.9 (8.1) 110.6 (9.2) 105.5 (11.8) 0.14 
Years of 
education 
13.5 (3.2) 14.8 (3.7) 13.4 (3.0) 14.9 (3.8) 0.58 
SAPS composite 
score 
6.0 [0-28] 0.0 [0-4] 30.0 [12-43] 16.0 [3-43] <0.001 
SANS composite 
score 
12.0 [0-25] 1.5 [0-4] 31.0 [16-43] 24.0 [12-35] <0.001 
Duration of 
illness 
- - 14.1 (5.9) 23.6 (11.2) 0.049 
Age at diagnosis - - 20.5 [17-37] 20.0 [16-27] 0.56 
Cannabis:  
 Years of regular   
  Useb 
 
19.7 (7.3), 




17.9 (6.5),  





 Age started  
  regular useb 
20.1 (5.4), 
range 12-34  
- 19.6 (6.2),  
range 13-29  
- 0.84 
 Current use  
  (days/mnth)c 
28 (4.6) - 25 (8.1) - 0.34 
 Current use  
  (cones/mnth)c 
636 (565) - 644 (344) - 0.97 
 Cumulative  
  exposure (past  
  10 yrs)c 
77816 
(66542) 
- 62925  
(25756) 
- 0.55 
Alcohol (stand.  
 drinks/week) 
7.0 [0-24] 4.0 [0-16] 7.0 [0-21] 0 [0-10] 0.028 
Tobacco  
 (cigarettes/day) 
20 [1-35] 0 [0-14] 20 [0-35] 7 [0-35] <0.001 
Intracranial 
cavityd 
1 546 237  
(94 018) 
1 607 590 
(126 386) 
 1 539 072  
(157 846) 
1 486 687  
(164 022) 
0.17 
Whole brain 1 310 780  1 374 123  1 293 879   1 239 308  0.063 
volumec (90 779) (105 673) (145 199) (155 894) 
Left hippocampal 
volumec 
2 849  
(270) 
3 240  
(423) 













3 144        
(383) 
3 003        
(264) 
0.01 
a Difference between the 4 groups or 2 groups depicted in each row from ANOVA, 
Kruskal-Wallis or Mann-Whitney tests.  
b Regular use was defined as at least twice a month 
c Cannabis users had used at this level for the majority of their drug-using careers; a 
‘cone’ is the small funnel into which cannabis is packed to consume through a water 
pipe in a single inhalation. Without the loss of sidestream smoke, the quantity of THC 
delivered by this method is estimated as equating three cones to one cigarette-sized 
joint.  Thus, the cannabis users with and without schizophrenia smoked the equivalent 
of 213 joints per month, or approximately 7 joints per day.  Estimates of lifetime dose 
beyond 10 years in these very long-term users became skewed and unreliable, hence 
the 10-year estimate was used in correlational analyses.  
d Measures of brain volumes corrected for intracranial cavity are in units of mm3.  
  
 
Fig. 1. Shape statistical analysis significance maps showing comparisons between schizophrenia 
patients without cannabis use (SZ–THC) versus healthy controls (CON) (top), healthy cannabis users 
(THC) versus CON (middle) and schizophrenia patients with cannabis use (SZ+THC) versus CON 
(bottom). Left hippocampus is depicted on the left and right hippocampus on the right, displaying 
superior and inferior views. For each view, raw p-value maps, FDR-corrected p-value maps, and mean 
difference magnitude displacement maps are shown (the latter visualising group test local effect size by 
displaying the local magnitude of deflation (in mm) on the overall mean surface (Styner et al., 2006)).  
  
 
Fig. 2. Correlations in the entire cannabis-smoking group (THC and SZ+THC) between hippocampal 
shape and cumulative exposure to cannabis over the past 10 years (top) and frequency of cannabis use 
in the past month (bottom), with left hippocampus on the left and right hippocampus on the right, 
displaying superior and inferior views. Raw p-value maps and Spearman’s rho-value maps are shown. 





Fig. 3. Correlations in the cannabis-using schizophrenia group (SZ+THC) between hippocampal shape 
and positive symptoms (SAPS score; top) and negative symptoms (SANS score; bottom), with left 
hippocampus on the left and right hippocampus on the right, displaying superior and inferior views. 
Raw p-value maps and Spearman’s rho-value maps are shown. The significance of these correlations 
did not survive FDR correction (FDR-corrected p-value maps not shown). 
 
 
